The clinical significance of CD16A interaction with antibody Fc region is demonstrated by the success of several FDA-approved cancer therapies, such as rituximab [6], trastuzumab [7], and cetuximab [8], all of which depend on CD16A receptor activation to exert their anti-tumor effects [9].Unlike the transient and relatively low-affinity interaction between the Fc domain of monoclonal antibodies (mAbs) and CD16A, Bispecific natural killer cell engager (BiKE) can establish a stable connection with any activating receptor on NK cells, which significantly enhance ADCC efficiency [10]. This evidence concerns the gene FCGR3A and neoplasm.